The Feasibility of Delivering Consumer-based Meditation Applications to Myeloproliferative Neoplasm Patients



Status:Completed
Conditions:Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:11/3/2018
Start Date:July 31, 2017
End Date:April 2, 2018

Use our guide to learn which trials are right for you!

Feasibility of Using a Consumer-based Mobile App to Improve Fatigue and Emotional Symptoms in Myeloproliferative Neoplasm Patients

This study was a four-group randomized pilot trial in myeloproliferative neoplasm (MPN)
patients. Patients were recruited nationally through organizational partners and social
media. Eligible and consented patients were enrolled into one of four groups, two of which
received varying orders of two consumer-based apps (unnamed consumer-based [CB] app and Calm
App) and two that received one of the apps alone for the second four weeks of the eight week
intervention after an educational control condition. Participants were asked to perform 10
min/day of smartphone-based meditation irrespective of the app and/or the order in which they
received the apps. Feasibility outcomes were measured at week five and nine with an online
survey. Feasibility outcomes were acceptability, demand, and limited efficacy for depression,
anxiety, pain intensity, sleep disturbance, sexual function, quality of life, global health,
and total symptom burden. The purpose of this study was to examine the feasibility of the use
of two different consumer-based meditation smartphone applications (i.e., apps) in MPN
patients.

Specific aim #1: Examine the feasibility of daily meditation delivered using a consumer-based
mobile app. Hypothesis: It will feasible to deliver smartphone-based meditation to MPN
patients.

Exploratory Aim: Explore the preliminary effects of daily meditation delivered using a
consumer-based mobile app on MPN self-report fatigue, anxiety, depression, pain intensity,
sleep disturbance, sexual function, global health, quality of life, and total symptom burden.
Hypothesis: There will be demonstrated preliminary effects on patient-reported outcomes in
MPN patients.

This was a four-group, randomized controlled trial with a cross-over design. Patients were
enrolled into one of four groups with varying order of receiving two consumer-based
meditation smartphone (i.e., unnamed consumer-based app [CB app], Calm app) apps in 4-week
increments over eight weeks. Group #1 received the CB App followed by the Calm app; Group #2
received the Calm app followed by the CB app; Group #3 received educational control followed
by the CB app and Group #4 received educational control followed by the Calm app.

MPN patients were recruited online through MPN organizational partners with a single page,
broad overview of the study and its requirements. The study was advertised as a smartphone
app meditation study. MPN patients interested in the study were asked to complete an online
eligibility questionnaire administered via Qualtrics. Researchers then checked completed
eligibility questionnaires as they were completed and emailed patients with their eligibility
status.

If ineligible, patients received an email stating their ineligibility status as well as links
to both consumer-based apps used in the study in case the ineligible participant was
interested in trying meditation. Eligible patients were invited to participate in a 20-minute
phone appointment in which the study details and informed consent were described in detail.
MPN patients who completed the intake appointment were then sent an informed consent
electronically via Qualtrics that included a place for their electronic signature.

Upon receipt of the completed informed consent, participants were randomly assigned to one of
four groups. A group assignment list was generated prior to study commencement with
randomizer.org. This pre-generated list was then used by research personnel to place
eligible, consented MPN patients into their group assignment (i.e., Group #1, Group #2, Group
#3, Group #4; described below) in the order in which they consented to participate.
Randomized participants were provided with a "welcome email" that contained a) a welcome
letter introducing them to the study, b) a calendar detailing important study dates, c)
instructions specific to the first assigned condition (i.e., CB app, Calm app, or educational
control) to be introduced for the first four weeks. After participants completed the first of
their two, four-week conditions (i.e., CB App, Calm, or control), they were provided with
another email that included instructions specific to their final condition (i.e., CB app,
Calm app, or educational control).

Unnamed Consumer-Based (CB) App The CB app was an already existing consumer-based smartphone
app. The first and second week consisted of meditation that was basic introductory, and
educational for those new to meditation. Weeks three and four consisted of a new and unique
daily meditation that study participants could select from a library of meditations within
the app. Each of the daily meditations had a different focus (e.g., grief, gratitude, choice,
letting go, etc.) and were ~10-12 minutes in length.

Description of Conditions

Calm App The Calm app was an already-existing, consumer-based meditation app. The first week
of the intervention included the "7 Days of Calm", which consists of seven days of
introductory meditations that incorporated basic, educational information for those new to
meditation while introducing brief experiential practices within that short period of time.
Weeks two through four consisted of the "Daily Calm", which is a new and unique daily guided
meditation that was provided by the app. Each of the daily meditations had a different focus
(e.g., practicing patience, loving-kindness, gratitude, etc.) and were ~10-12 minutes in
length.

Educational Control The control condition was provided with educational material handout that
was developed by the research team prior to the study. The handout addressed MPN patient
fatigue (e.g., What causes fatigue?) as well as examples of and information related to
evidence-based fatigue-management strategies.

Description of Groups

Group #1 (CB App + Calm) Group #1 was assigned the CB App (Weeks 1-4) and the Calm app (Weeks
5-8). During weeks 1-4, participants were asked to complete four weeks of meditation on the
CB App via their smartphone for a minimum of 10 min/day (i.e., ~70 min/week) but encouraged
to do more if they could. During weeks 5-8, participants were asked to complete four weeks of
meditation on the Calm app via their smartphone for a minimum of 10 min/day (i.e., ~70
min/week) but encouraged to do more if they could.

Group #2 (Calm APP + CB App) Group #2 was assigned the Calm app (Weeks 1-4) and the CB app
(Weeks 5-8). During weeks 1-4, participants were asked to complete four weeks of meditation
on the Calm app via their smartphone for a minimum of 10 min/day (i.e., ~70 min/week) but
encouraged to do more if they could. During weeks 5-8, participants were asked to complete
four weeks of meditation on the CB app via their smartphone for a minimum of 10 min/day
(i.e., ~70 min/week) but encouraged to do more if they could.

Group #3 (Control + CB App) Group #3 was assigned educational control (Weeks 1-4) and the CB
app (Weeks 5-8). During weeks 1-4, participants were provided the educational material
handout and asked to maintain their normal routine. During weeks 5-8, participants were asked
to complete four weeks of meditation on the CB app via their smartphone for a minimum of 10
min/day (i.e., ~70 min/week) but encouraged to do more if they could.

Group #4 (Control + Calm) Group #4 was assigned educational control (Weeks 1-4) and the Calm
app (Weeks 5-8). During weeks 1-4, participants were provided the educational material
handout and asked to maintain their normal routine. During weeks 5-8, participants were asked
to complete four weeks of meditation on the Calm app via their smartphone for a minimum of 10
min/day (i.e., ~70 min/week) but encouraged to do more if they could.

All study participants completed patient-reported outcomes measures via an online
questionnaire at baseline (week 0), mid-point (week 5), and post-intervention (week 9).

Inclusion Criteria:

- had a diagnosis of MPN (i.e., essential thrombocythemia, polycythemia vera, or
myelofibrosis) identified by treating physician

- owned a mobile smartphone and were willing to download and use a meditation app (i.e.,
CB or Calm)

- could read and understand English

- were age 18 years or older

- were willing to be randomized to one of four groups: 1) CB 4 wks/Calm 4 wks, 2) Calm 4
wks/CB 4 wks, 3) educational material 4 wks/CB 4 wks, and 4) educational material 4
wks/Calm 4 wks,

Exclusion Criteria:

- engaged in ≥10 min/day of meditation on ≥5 days/week for the past 6 months

- engaged in ≥60 min/week of tai chi, qigong, or yoga each week

- utilized either App #1 or Calm

- resided outside of the United States of America
We found this trial at
1
site
Phoenix, Arizona 85004
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials